# SPYRAL DYSTAL Renal Denervation Global Clinical Study

Study · id `cardio:ct-nct04311086` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04311086](<https://clinicaltrials.gov/study/NCT04311086>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04311086

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

## Technical summary

Registry record NCT04311086. Allocation not applicable; no masking; primary purpose treatment. Start 2020-06-12 (actual); primary completion 2022-12-22 (actual). Results posted on 2024-04-17.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 128 participants (enrolled count; ClinicalTrials.gov record NCT04311086, source copy `cardio:ctgov-nct04311086-2024-04-17`, retrieved 2026-10-26)
- Started: 2020-06-12 (actual) (ClinicalTrials.gov record NCT04311086, source copy `cardio:ctgov-nct04311086-2024-04-17`, retrieved 2026-10-26)
- Primary completion: 2022-12-22 (actual) (ClinicalTrials.gov record NCT04311086, source copy `cardio:ctgov-nct04311086-2024-04-17`, retrieved 2026-10-26)
- Completion: 2022-12-22 (actual) (ClinicalTrials.gov record NCT04311086, source copy `cardio:ctgov-nct04311086-2024-04-17`, retrieved 2026-10-26)
- Results first posted: 2024-04-17 (ClinicalTrials.gov record NCT04311086, source copy `cardio:ctgov-nct04311086-2024-04-17`, retrieved 2026-10-26)
- Countries: United States; Germany; Greece; United Kingdom (ClinicalTrials.gov record NCT04311086, source copy `cardio:ctgov-nct04311086-2024-04-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04311086-2024-04-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: SPYRAL DYSTAL Renal Denervation Global Clinical Study
- Condition: Hypertension
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Intervention (Device): Renal Denervation (Symplicity Spyral™)
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

## Provenance

Content hash: fc6a9820d67a3e0da8e926dff316bd6250000f2148f87ec55bfe6c4930edfd87
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
